The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
Primary Purpose
Glabellar Frown Lines
Status
Recruiting
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
PROTOXIN
Botox®
Sponsored by

About this trial
This is an interventional treatment trial for Glabellar Frown Lines focused on measuring Glabellar Lines, Botulinum toxin, Botulinum toxin type A
Eligibility Criteria
Inclusion Criteria:
- Men and women aged between 19 to 65 years old
- Subjects attaining ≥grade 2 (moderate) in the investigator's rating of the severity of glabella lines at maximum frown
- Those who understand and comply with clinical trial procedures and visit schedules
- Subjects who voluntarily decides to participate and signs the consent form after hearing the explanation of this clinical trial.
Exclusion Criteria
Those with or accompanied by the following diseases at the time of screening
- Subjects with Neuromuscular Junction Disorder that may affect neuromuscular action
- Subjects with previous history of weakness or paralysis in the forehead area
- Subjects with infection, skin disorders, or scars at the glabellar region
- Subjects with wrinkles that physically prevent wrinkles from spreading, such as when wrinkles are not spread out by hand
- Subjects who is administering a drug with muscle relaxation within four weeks of screening.
- Subjects who have taken Aspirin and NSAIDs within 7 days prior to administration of the investigational drug
- Subjects with surgical history who may affect wrinkles around the forehead or glabellar region
- Subjects who have planned facial cosmetic procedure during the clinical trial
- Subjects who have been administered similar drugs within 12 weeks (Botulinum toxin type A) or within 16 weeks (Botulinum toxin type B) before screening
- Subjects who are expected to administer botulinum toxin preparations other than Investigational product during the clinical trial period
- Subjects with allergy or hypersensitivity to the botulinum toxin or their components
- A history of drug or alcohol abuse
- Anxiety disorders or other significant mental disorders based on the judgment of an investigator
- Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception
- Pregnant or lactating women
- Subjects with severe comorbidities or acute diseases that does not suitable for participation in clinical trials
- Those who participated in other clinical trials/clinical medical device trials within 30 days prior to screening and who received Investigational product/medical devices/procedures, or those who had less than 5 times the half-life of the Investigational product
- Subjects who are not eligible for this study based on the judgment of an investigator
Sites / Locations
- Kyung Hee University HospitalRecruiting
- Chung-Ang University HospitalRecruiting
- Konkuk University HospitalRecruiting
- Nowon Eulji Medical Center
- Pusan National University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
PROTOXIN(Phase Ⅲ)
Botox® (Phase Ⅲ)
Arm Description
PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL)
Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
Outcomes
Primary Outcome Measures
Proportion of subjects achieving at least a 2-grade improvement from baseline on the facial wrinkle scale of GL at maximum frown at Week 4
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Secondary Outcome Measures
Investigator-rated improvement rate of glabellar lines at maximum frown
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Participant-rated improvement rate of glabellar lines at maximum frown
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Investigator-rated improvement rate of glabellar lines at rest
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Participant-rated improvement rate of glabellar lines at rest
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Independent photo evaluator-rated improvement rate of glabellar lines at frown
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Independent photo evaluator-rated improvement rate of glabellar lines at rest
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Participant-rated satisfaction after treatment
Participant evaluate the level of satisfaction by Patient Satisfaction(PS) 7-grade score(1 to 7) where 1 = very dissatisfied and 7 = very satisfied
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05364580
Brief Title
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
Official Title
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Compare the Efficacy and Safety of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 6, 2023 (Actual)
Primary Completion Date
July 1, 2023 (Anticipated)
Study Completion Date
September 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Protox Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a total of 20U(4U/0.1mL each) in five sites of the glabellar lines. The investigational product is administered once, maintaining double-blind for a total of 16 weeks of observation. Thereafter, efficacy and safety are assessed by comparing with BOTOX® after regular visits conducted at 4,8,12 and 16 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glabellar Frown Lines
Keywords
Glabellar Lines, Botulinum toxin, Botulinum toxin type A
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
274 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PROTOXIN(Phase Ⅲ)
Arm Type
Experimental
Arm Description
PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL)
Arm Title
Botox® (Phase Ⅲ)
Arm Type
Active Comparator
Arm Description
Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
Intervention Type
Biological
Intervention Name(s)
PROTOXIN
Intervention Description
Botulinum toxin Type A
Intervention Type
Biological
Intervention Name(s)
Botox®
Intervention Description
Botulinum toxin Type A
Primary Outcome Measure Information:
Title
Proportion of subjects achieving at least a 2-grade improvement from baseline on the facial wrinkle scale of GL at maximum frown at Week 4
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
4 weeks post injection compared to baseline
Secondary Outcome Measure Information:
Title
Investigator-rated improvement rate of glabellar lines at maximum frown
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
Week 8, 12, 16
Title
Participant-rated improvement rate of glabellar lines at maximum frown
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
Week 4, 8, 12, 16
Title
Investigator-rated improvement rate of glabellar lines at rest
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
Week 4, 8, 12, 16
Title
Participant-rated improvement rate of glabellar lines at rest
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
Week 4, 8, 12, 16
Title
Independent photo evaluator-rated improvement rate of glabellar lines at frown
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
Week 4, 8, 12, 16
Title
Independent photo evaluator-rated improvement rate of glabellar lines at rest
Description
The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe
Time Frame
Week 4, 8, 12, 16
Title
Participant-rated satisfaction after treatment
Description
Participant evaluate the level of satisfaction by Patient Satisfaction(PS) 7-grade score(1 to 7) where 1 = very dissatisfied and 7 = very satisfied
Time Frame
Week 4, 8, 12, 16
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men and women aged between 19 to 65 years old
Subjects attaining ≥grade 2 (moderate) in the investigator's rating of the severity of glabella lines at maximum frown
Those who understand and comply with clinical trial procedures and visit schedules
Subjects who voluntarily decides to participate and signs the consent form after hearing the explanation of this clinical trial.
Exclusion Criteria
Those with or accompanied by the following diseases at the time of screening
Subjects with Neuromuscular Junction Disorder that may affect neuromuscular action
Subjects with previous history of weakness or paralysis in the forehead area
Subjects with infection, skin disorders, or scars at the glabellar region
Subjects with wrinkles that physically prevent wrinkles from spreading, such as when wrinkles are not spread out by hand
Subjects who is administering a drug with muscle relaxation within four weeks of screening.
Subjects who have taken Aspirin and NSAIDs within 7 days prior to administration of the investigational drug
Subjects with surgical history who may affect wrinkles around the forehead or glabellar region
Subjects who have planned facial cosmetic procedure during the clinical trial
Subjects who have been administered similar drugs within 12 weeks (Botulinum toxin type A) or within 16 weeks (Botulinum toxin type B) before screening
Subjects who are expected to administer botulinum toxin preparations other than Investigational product during the clinical trial period
Subjects with allergy or hypersensitivity to the botulinum toxin or their components
A history of drug or alcohol abuse
Anxiety disorders or other significant mental disorders based on the judgment of an investigator
Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception
Pregnant or lactating women
Subjects with severe comorbidities or acute diseases that does not suitable for participation in clinical trials
Those who participated in other clinical trials/clinical medical device trials within 30 days prior to screening and who received Investigational product/medical devices/procedures, or those who had less than 5 times the half-life of the Investigational product
Subjects who are not eligible for this study based on the judgment of an investigator
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Park Jinhong
Phone
+82-70-4018-8208
Email
jhpark@iprotox.com
First Name & Middle Initial & Last Name or Official Title & Degree
Lee Hyungyu
Phone
+82-70-4018-8218
Email
hglee2020@iprotox.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kim Beomjoon
Organizational Affiliation
Chung-Ang University Hospital, Chung-Ang University College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lee Yangwon
Organizational Affiliation
Konkuk University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kim Moonbeom
Organizational Affiliation
Pusan National University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lee Jonghoon
Organizational Affiliation
Nown Eulji Medical Center, Eulji University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Shin Minkyung
Organizational Affiliation
Kyunghee University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kyung Hee University Hospital
City
Seoul
State/Province
Dongdaemun-gu
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Chung-Ang University Hospital
City
Seoul
State/Province
Gwangjin-gu
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Konkuk University Hospital
City
Seoul
State/Province
Gwangjin-gu
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Nowon Eulji Medical Center
City
Seoul
State/Province
Nowon-gu
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Pusan National University Hospital
City
Pusan
State/Province
Seo-gu
Country
Korea, Republic of
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
We'll reach out to this number within 24 hrs